ISSN 1301-143X | E-ISSN 1309-1484
Role of Broadly Neutralizing Antibodies in the Controlling of HIV-1 Infection
1 Okmeydanı Eğitim ve Araştırma Hastanesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, İstanbul, Türkiye  
Klimik Dergisi 2019; 32: 112-116
DOI: 10.5152/kd.2019.27
Key Words: HIV-1, broadly neutralizing antibodies, immunotherapy


Broadly neutralizing antibodies (bNAbs) are monoclonal antibodies capable of inactivating a wide spectrum of HIV-1 subtypes and variants. These immunoglobulins were identified in 2009 in a small number of HIV-infected people. Their appearance during the process of natural infection was found to be substantially retarded and complicated. Vaccine applications have not been to produce such antibodies with sufficient properties. Thanks to the new technological advances, numerous neutralizing antibodies were designed and obtained by modelling natural antibodies. It is expected that a strong, long-lasting, easy-to-administer, low-side-effect bNAb combinations will provide significant improvement in the control and treatment of HIV infection in the not-distant future. In this review, mechanisms of action of these antibodies and the current stage of clinical research aimed at evaluation of their efficacy are reviewed. Klimik Dergisi 2019; 32(2): 112-6.

Cite this article as: Yıldırmak T. [Role of broadly neutralizing antibodies in the controlling  of HIV-1 infection]. Klimik Derg. 2019; 32(2): 112-6. Turkish.

Key Words
Reviewer's Corner
Author's Corner
Frequently Asked Questions
AVES | Copyright © 2019 Turkish Society of Clinical Microbiology Infectious Diseases | Latest Update: 19.09.2019